Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Indomethacin Extended-Release Capsules USP, 75 mg. The drug is indicated for use in painful and inflammatory conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute painful shoulder (bursitis and/or tendinitis).
The drug will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad. The group now has more than 155 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
